Donald Trump’s threat of a 100% tariff on UK pharmaceuticals is creating a ripple of fear that extends far beyond the drug industry, chilling the business climate for other sectors that now wonder if they could be next. The targeted nature of the attack sends a clear message: no industry is safe, especially if it was not explicitly covered in a trade agreement.
This “contagion of fear” is a significant, if less visible, consequence of the trade dispute. Leaders in other UK sectors, such as technology, finance, and specialty manufacturing, are undoubtedly watching the pharma crisis with a growing sense of unease. They are seeing firsthand how quickly a promise of “preferential treatment” can be replaced by a threat of economic annihilation.
The situation exposes the inadequacy of the UK’s partial trade deal with the US. While it protected cars and steel, it created an implicit vulnerability for everyone else. The current crisis serves as a stark warning to any sector that believed it was flying under the radar. The US has shown it is willing to pick off industries one by one.
This fear can have a tangible economic impact. It can lead to a more cautious approach to investment and expansion, as businesses add a new layer of political risk to their calculations. It may also prompt some companies to proactively shift investment to the US as a defensive measure, even without a direct threat, to avoid becoming the next target.
As the UK government fights to save its pharmaceutical industry, it is also, in effect, fighting to contain this ripple of fear. If it can secure a favorable outcome, it might restore a degree of confidence. If it fails, the chill that is currently gripping the pharmaceutical sector could spread throughout the entire British economy.